Advertisement
Survey Series
For Advertisers
|
|
||||
|
Biotech Financing Freed
Money is available again for biotechs, but competition is stiff
The Scientist 2004, 18(2):42
|
||||
|
|
||||
|
After several punishing years, the window for biotechnology financing in the US appears to be reopening, though mainly for larger companies with a strong product pipeline, leaving early-stage biotechs to scrap over a tightening pool of federal and local funds. Biotech companies raked in more than $12 billion (US) in 2003, the industry's second highest annual total, but well behind the $32 million raised in the boom year of 2000.
|
|
|||||||||
|
|||||||||
|
